Acknowledgements
NB, TriMaster
DIABETES
We thank all study participants. We gratefully acknowledge the TriMaster central coordinating team, all members of the TriMaster study group, MASTERMIND consortium, the Data Monitoring Committee, and the Trial Steering Committee.). In particular, we thank Prof Stephen Senn for his invaluable guidance on the analysis for this trial. In addition, we thank the Exeter NIHR Clinical Research Facility and the Exeter Clinical Trials Unit (CTU), particularly Lynne Quinn and Siobhan Creanor for their support with the study, and the CTU Data Team. We thank Alison Kerridge and Shirley Todd of the R&D and Pharmacy Departments at the Royal Devon and Exeter NHS Foundation Trust for support and sponsorship. Full acknowledgements of all members of the trial study group and committees are listed in the primary paperThis trial is part of the MASTERMIND (MRC APBI Stratification and Extreme Response Mechanism IN Diabetes) consortium and is supported by the UK Medical Research Council study grant number MR/N00633X/1. The TriMaster trial was supported by the National Institute for Health and Care Research Exeter Biomedical Research Centre and National Institute for Health and Care Research Exeter Clinical Research Facility. The funder had no role in study design, data collection, data analysis, data interpretation, decision to publish or preparation of the manuscript. The views expressed are those of the author(s) and not necessarily those of the MRC, the NIHR or the Department of Health and Social Care. For the purpose of open access, the author has applied a ‘Creative Commons Attribution (CC BY) licence to any Author Accepted Manuscript version arising.
BS helped design the study, wrote the statistical analysis plan, performed analysis, and drafted the manuscript. CA was the trial manager, helped design the study, performed analysis in parallel, and drafted the manuscript. MS helped design the patient preference questionnaires and edited the manuscript, NB advised on design of the patient preference questionnaires and edited the manuscript. AJ advised on study design and edited the manuscript. NS advised on study design and edited the manuscript. RH advised on study design and edited the manuscript. EP helped design the study and edited the manuscript. AH was Chief Investigator on the study, led the study design, advised on analysis, and edited the manuscript.
NS is supported by a BHF Centre of Excellence Award (RE/18/6/34217). RH is an Emeritus National Institute for Health Research Senior Investigator. AH was a Wellcome Senior Investigator (098395/Z/12/Z) and is an emeritus Senior Investigator at the NIHR. AH, BS, MS, AG and CA are supported by the NIHR Exeter Clinical Research Facility and National Institute for Health and Care Research Exeter Biomedical Research Centre. EP has received Honoraria from Lilly, Sanofi and Illumina. NS has consulted for and/or received speaker honoraria from Abbott Laboratories, Afimmune, Amgen, Astrazeneca, Boehringer Ingelheim, Eli-Lilly, Hanmi Pharmaceuticals, Janssen, MSD, Novo Nordisk, Novartis, Sanofi and Pfizer and received grant funding paid to his University from AstraZeneca, Boehringer Ingelheim, Novartis and Roche Diagnostics. RRH reports research support from AstraZeneca, Bayer and Merck Sharp & Dohme, and personal fees from Anji Pharmaceuticals, AstraZeneca, Novartis and Novo Nordisk. The remaining authors declare no competing interests.